In vitro Activity and Safety Assessment of New Synthesized Thiazolo Pyrimidine Derivatives Augmented with Albendazole against Echinococcus Multilocularis Metacestodes in Balb/C Mice
Abstract
Purpose: To synthesis a series of novel thiazolo pyrimidine derivatives and evaluate them in vitro for their safety and anthelmintic activity against E. multilocularis metacestodes using BALB/c mice.
Methods: A new series of substituted amino thiazole, hydrazinothiazole and thiazolo pyrimidine derivatives (2-6) were synthesized by reaction of compound 1 with potassium isothiocyanate to give the corresponding compound 2, which was used as starting material. The physicochemical characterization of these derivatives was carried out by nuclear magnetic resonance spectroscopy (1HNMR) and mass spectroscopy (MS).The purity of the compounds was determined by elemental analysis. Safety and anthelminthic activity of the compounds against E. multilocularis metacestodes was evaluated in vitro by i) viability assessment and relative abundance of 14-3-3 mRNA determination in E. multilocularis metacestodes-suspensions treated with 2, 5 and 10 μM concentrations of each compound separately. ii) bioassay at 15 weeks post-inoculation of mice by E. multilocularis suspensions-treated with 30 μM albendazole (ABZ), 10 μM thiazolopyrimidine derivative 5 (TPYDa) and a combination of both. Liver functions of all mice were tested before mice sacrifice.
Results: TPYDa emerged as the active anthelmintic compound of the series against E. multilocularis metacestodes viability (activity, 60 %) compared with ABZ (activity, 63 %). When TPYDa was combined with ABZ, the activity reached 86 %. No mortality was found and liver function was normal in all mice during the studies.
Conclusion: The compound, TPYDa, can serve as a lead molecule for further development to a clinically useful novel class of anthelmintic agents.
Keywords: Thiazolopyrimidine, Synthesis, Echinococcosis, Mice, Chemotherapy
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
